General MedicationsNASALStandard
SPRAVATO
ESKETAMINE HYDROCHLORIDE
Standard Dose
EQ 28MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary
Approval overview SPRAVATO is listed in Drugs@FDA under application 211243 (NDA).
Review priority: N/A Marketing status: Prescription Active ingredient ESKETAMINE HYDROCHLORIDE Form and strength SPRAY;NASAL - EQ 28MG BASE Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2026-01-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview SPRAVATO is listed in Drugs@FDA under application 211243 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient ESKETAMINE HYDROCHLORIDE Form and strength SPRAY;NASAL - EQ 28MG BASE Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2026-01-23 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: N/A
Interaction Notes
- No interaction notes stored yet.